APA (7th ed.) Citation

Fenioux, C., Louvet, C., Charton, E., Rozet, F., Ropert, S., Prapotnich, D., . . . Bennamoun, M. (2019). Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration‐resistant prostate cancer. BJU International, 123(2), 300. https://doi.org/10.1111/bju.14511

Chicago Style (17th ed.) Citation

Fenioux, Charlotte, et al. "Switch from Abiraterone Plus Prednisone to Abiraterone Plus Dexamethasone at Asymptomatic PSA Progression in Patients with Metastatic Castration‐resistant Prostate Cancer." BJU International 123, no. 2 (2019): 300. https://doi.org/10.1111/bju.14511.

MLA (9th ed.) Citation

Fenioux, Charlotte, et al. "Switch from Abiraterone Plus Prednisone to Abiraterone Plus Dexamethasone at Asymptomatic PSA Progression in Patients with Metastatic Castration‐resistant Prostate Cancer." BJU International, vol. 123, no. 2, 2019, p. 300, https://doi.org/10.1111/bju.14511.